First Clinical Isolation of an Azole-Resistant Aspergillus fumigatus Isolate Harboring a TR46 Y121F T289A Mutation in South America

Antimicrob Agents Chemother. 2018 Sep 24;62(10):e00872-18. doi: 10.1128/AAC.00872-18. Print 2018 Oct.

Abstract

One of the most recently described Aspergillus fumigatusCYP51A-mediated azole resistance mechanisms is TR46 Y121F T289A. Clinical A. fumigatus strains harboring these substitutions have been reported worldwide, with the exception of South America. We describe the first clinical A. fumigatus strain with this resistance mechanism isolated from an Argentinian patient. The strain was isolated in 2009 (1 year after the first-described mutant in United States), demonstrating that these alleles were scattered worldwide earlier than previously thought.

Keywords: Aspergillus fumigatus; CYP51A; South America; TR46; TR46 Y121F T289A mutation; azole; resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Aspergillus fumigatus / drug effects
  • Aspergillus fumigatus / genetics*
  • Azoles / pharmacology*
  • Drug Resistance, Fungal / genetics
  • Fungal Proteins / genetics
  • Mutation / genetics
  • South America

Substances

  • Antifungal Agents
  • Azoles
  • Fungal Proteins